Luis Miramontes

Luis Miramontes, working as a graduate student researcher at the Syntex laboratory in Mexico City, successfully synthesized norethindrone (also known as norethisterone) in 1951 by modifying the structure of progesterone to create an orally active progestin. His synthesis involved a key chemical step using a specific steroid intermediate that made the compound stable enough to survive oral administration, which natural progesterone could not do.

Miramontes worked under the direction of Carl Djerassi, an Austrian-American chemist, and Luis Ernesto Miramontes was supervised by George Rosenkranz, a Hungarian-Mexican chemist who served as Syntex's research director. The 1951 synthesis was formally credited to all three researchers in the published patent, though Miramontes is recognized as having personally performed the critical laboratory synthesis.

Norethindrone became one of the key active ingredients in the first commercially available oral contraceptive pill, which was approved by the U.S. Food and Drug Administration in 1960. Its oral bioactivity solved the fundamental problem that natural progesterone was ineffective when taken as a pill, making practical hormonal contraception possible.

Although Miramontes physically performed the critical synthesis of norethindrone, public attention largely focused on Carl Djerassi, who became widely known as the 'father of the pill' through his later publications and media presence. Miramontes's role as a young Mexican graduate student was frequently minimized or omitted in mainstream accounts, though his name does appear alongside Djerassi and Rosenkranz on the original U.S. patent filed in 1951.